Cardiff Oncology issues warrants to buy 9,303,136 shares in registered direct offering
CRDF•Warrant structure and timing
The warrants carry a $1.31 exercise price, become exercisable after six months and authorized-share approval, and expire 5.5 years later.
Expected proceeds and closing
Gross proceeds are expected at about $10 million, with closing targeted for July 16, 2026.
Registered direct offering terms
Cardiff Oncology launched a registered direct offering with warrants covering 9,303,136 common shares.
Warrants were priced alongside the shares at $1.05, with officer and director participation at $1.44.
